Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD)
Not yet recruiting · NCT07462455 · Registry updated 2026-09-14Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) | metabolic dysfunction-associated steatohepatitis | Not yet recruiting | Phase 1 | 2026-09-14 | NCT07462455 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Tsinghua Changgeng Hospital | 16 |
| Xiamen Amoytop Biotech Co., Ltd. | 11 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Beijing Tsinghua Changgeng Hospital | Beijing | China | 3 |
| The First Affiliated Hospital of Xi'an Jiaotong University | Xi'an | China | 39 |
| The First Affiliated Hospital of Xiamen University | Xiamen | China | 40 |
| Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine | Shanghai | China | 6 |